Long Shortz with Orthocell: Remplir gets FDA green light

Tylah Tully chats with Orthocell’s (ASX:OCC) managing director and CEO Paul Anderson to talk through the company’s major milestone, after 10 year its received FDA approval for its nerve repair product Remplir.

But its plans for global expansion don’t stop there, its eyeing several other countries to continue its mission.

Watch the video to hear all about it.

This video was developed in collaboration with Orthocell, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.